nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprazolam—CYP3A4—bone cancer	0.82	1	CbGaD
Alprazolam—Ketazolam—CYP3A4—bone cancer	0.000678	0.0933	CrCbGaD
Alprazolam—Chlordiazepoxide—CYP3A4—bone cancer	0.000566	0.0779	CrCbGaD
Alprazolam—Clonazepam—CYP3A4—bone cancer	0.000547	0.0752	CrCbGaD
Alprazolam—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000544	0.0527	CbGpPWpGaD
Alprazolam—Clorazepate—CYP3A4—bone cancer	0.000529	0.0728	CrCbGaD
Alprazolam—Clobazam—CYP3A4—bone cancer	0.000479	0.066	CrCbGaD
Alprazolam—Quazepam—CYP3A4—bone cancer	0.000465	0.064	CrCbGaD
Alprazolam—Upper respiratory tract infection—Methotrexate—bone cancer	0.000441	0.00272	CcSEcCtD
Alprazolam—Liver function test abnormal—Doxorubicin—bone cancer	0.000439	0.00271	CcSEcCtD
Alprazolam—Flunitrazepam—CYP3A4—bone cancer	0.000439	0.0604	CrCbGaD
Alprazolam—Dyspnoea—Cisplatin—bone cancer	0.000439	0.00271	CcSEcCtD
Alprazolam—Photosensitivity reaction—Methotrexate—bone cancer	0.000433	0.00267	CcSEcCtD
Alprazolam—Breast disorder—Doxorubicin—bone cancer	0.00043	0.00265	CcSEcCtD
Alprazolam—Decreased appetite—Cisplatin—bone cancer	0.000428	0.00264	CcSEcCtD
Alprazolam—Nasopharyngitis—Doxorubicin—bone cancer	0.000425	0.00262	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Cisplatin—bone cancer	0.000425	0.00262	CcSEcCtD
Alprazolam—Drowsiness—Methotrexate—bone cancer	0.000423	0.00261	CcSEcCtD
Alprazolam—Infestation—Methotrexate—bone cancer	0.000423	0.00261	CcSEcCtD
Alprazolam—Infestation NOS—Methotrexate—bone cancer	0.000423	0.00261	CcSEcCtD
Alprazolam—Depression—Methotrexate—bone cancer	0.000422	0.0026	CcSEcCtD
Alprazolam—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00042	0.00259	CcSEcCtD
Alprazolam—Muscular weakness—Doxorubicin—bone cancer	0.00042	0.00259	CcSEcCtD
Alprazolam—Dysuria—Epirubicin—bone cancer	0.000415	0.00256	CcSEcCtD
Alprazolam—Upper respiratory tract infection—Epirubicin—bone cancer	0.000413	0.00255	CcSEcCtD
Alprazolam—Dysphagia—Doxorubicin—bone cancer	0.000411	0.00254	CcSEcCtD
Alprazolam—Influenza—Doxorubicin—bone cancer	0.000411	0.00254	CcSEcCtD
Alprazolam—Estazolam—CYP3A4—bone cancer	0.00041	0.0565	CrCbGaD
Alprazolam—Pollakiuria—Epirubicin—bone cancer	0.00041	0.00253	CcSEcCtD
Alprazolam—Sweating—Methotrexate—bone cancer	0.000406	0.0025	CcSEcCtD
Alprazolam—Photosensitivity reaction—Epirubicin—bone cancer	0.000406	0.0025	CcSEcCtD
Alprazolam—Feeling abnormal—Cisplatin—bone cancer	0.000405	0.0025	CcSEcCtD
Alprazolam—Weight increased—Epirubicin—bone cancer	0.000404	0.0025	CcSEcCtD
Alprazolam—Weight decreased—Epirubicin—bone cancer	0.000402	0.00248	CcSEcCtD
Alprazolam—Hepatobiliary disease—Methotrexate—bone cancer	0.0004	0.00247	CcSEcCtD
Alprazolam—Epistaxis—Methotrexate—bone cancer	0.000399	0.00246	CcSEcCtD
Alprazolam—Drowsiness—Epirubicin—bone cancer	0.000396	0.00244	CcSEcCtD
Alprazolam—Infestation—Epirubicin—bone cancer	0.000396	0.00244	CcSEcCtD
Alprazolam—Infestation NOS—Epirubicin—bone cancer	0.000396	0.00244	CcSEcCtD
Alprazolam—Nitrazepam—CYP3A4—bone cancer	0.000396	0.0545	CrCbGaD
Alprazolam—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000393	0.0381	CbGpPWpGaD
Alprazolam—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000393	0.00242	CcSEcCtD
Alprazolam—Adinazolam—CYP3A4—bone cancer	0.000391	0.0538	CrCbGaD
Alprazolam—Body temperature increased—Cisplatin—bone cancer	0.000389	0.0024	CcSEcCtD
Alprazolam—Jaundice—Epirubicin—bone cancer	0.000386	0.00238	CcSEcCtD
Alprazolam—Dysuria—Doxorubicin—bone cancer	0.000384	0.00237	CcSEcCtD
Alprazolam—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000382	0.00236	CcSEcCtD
Alprazolam—Hepatitis—Methotrexate—bone cancer	0.00038	0.00235	CcSEcCtD
Alprazolam—Sweating—Epirubicin—bone cancer	0.00038	0.00234	CcSEcCtD
Alprazolam—Pollakiuria—Doxorubicin—bone cancer	0.00038	0.00234	CcSEcCtD
Alprazolam—Prazepam—CYP3A4—bone cancer	0.000378	0.052	CrCbGaD
Alprazolam—Urinary tract disorder—Methotrexate—bone cancer	0.000375	0.00232	CcSEcCtD
Alprazolam—Photosensitivity reaction—Doxorubicin—bone cancer	0.000375	0.00232	CcSEcCtD
Alprazolam—Hepatobiliary disease—Epirubicin—bone cancer	0.000375	0.00231	CcSEcCtD
Alprazolam—Weight increased—Doxorubicin—bone cancer	0.000374	0.00231	CcSEcCtD
Alprazolam—Epistaxis—Epirubicin—bone cancer	0.000374	0.00231	CcSEcCtD
Alprazolam—Urethral disorder—Methotrexate—bone cancer	0.000373	0.0023	CcSEcCtD
Alprazolam—Weight decreased—Doxorubicin—bone cancer	0.000372	0.0023	CcSEcCtD
Alprazolam—Drowsiness—Doxorubicin—bone cancer	0.000367	0.00226	CcSEcCtD
Alprazolam—Infestation—Doxorubicin—bone cancer	0.000367	0.00226	CcSEcCtD
Alprazolam—Infestation NOS—Doxorubicin—bone cancer	0.000367	0.00226	CcSEcCtD
Alprazolam—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000363	0.00224	CcSEcCtD
Alprazolam—Hypersensitivity—Cisplatin—bone cancer	0.000363	0.00224	CcSEcCtD
Alprazolam—Erythema multiforme—Methotrexate—bone cancer	0.000359	0.00222	CcSEcCtD
Alprazolam—Jaundice—Doxorubicin—bone cancer	0.000357	0.0022	CcSEcCtD
Alprazolam—Hepatitis—Epirubicin—bone cancer	0.000356	0.00219	CcSEcCtD
Alprazolam—Eye disorder—Methotrexate—bone cancer	0.000355	0.00219	CcSEcCtD
Alprazolam—Tinnitus—Methotrexate—bone cancer	0.000354	0.00219	CcSEcCtD
Alprazolam—Hypoaesthesia—Epirubicin—bone cancer	0.000354	0.00218	CcSEcCtD
Alprazolam—Asthenia—Cisplatin—bone cancer	0.000353	0.00218	CcSEcCtD
Alprazolam—Cardiac disorder—Methotrexate—bone cancer	0.000353	0.00218	CcSEcCtD
Alprazolam—Flurazepam—CYP3A4—bone cancer	0.000352	0.0485	CrCbGaD
Alprazolam—Triazolam—CYP3A4—bone cancer	0.000352	0.0484	CrCbGaD
Alprazolam—Sweating—Doxorubicin—bone cancer	0.000351	0.00217	CcSEcCtD
Alprazolam—Urinary tract disorder—Epirubicin—bone cancer	0.000351	0.00217	CcSEcCtD
Alprazolam—Oedema peripheral—Epirubicin—bone cancer	0.00035	0.00216	CcSEcCtD
Alprazolam—Connective tissue disorder—Epirubicin—bone cancer	0.000349	0.00216	CcSEcCtD
Alprazolam—Urethral disorder—Epirubicin—bone cancer	0.000349	0.00215	CcSEcCtD
Alprazolam—Hepatobiliary disease—Doxorubicin—bone cancer	0.000347	0.00214	CcSEcCtD
Alprazolam—Epistaxis—Doxorubicin—bone cancer	0.000346	0.00213	CcSEcCtD
Alprazolam—Angiopathy—Methotrexate—bone cancer	0.000345	0.00213	CcSEcCtD
Alprazolam—Mediastinal disorder—Methotrexate—bone cancer	0.000343	0.00211	CcSEcCtD
Alprazolam—Oxazepam—CYP3A4—bone cancer	0.000341	0.0469	CrCbGaD
Alprazolam—Chills—Methotrexate—bone cancer	0.000341	0.0021	CcSEcCtD
Alprazolam—Temazepam—CYP3A4—bone cancer	0.000337	0.0463	CrCbGaD
Alprazolam—Diarrhoea—Cisplatin—bone cancer	0.000337	0.00208	CcSEcCtD
Alprazolam—Erythema multiforme—Epirubicin—bone cancer	0.000336	0.00208	CcSEcCtD
Alprazolam—Mental disorder—Methotrexate—bone cancer	0.000333	0.00205	CcSEcCtD
Alprazolam—Eye disorder—Epirubicin—bone cancer	0.000332	0.00205	CcSEcCtD
Alprazolam—Tinnitus—Epirubicin—bone cancer	0.000332	0.00205	CcSEcCtD
Alprazolam—Malnutrition—Methotrexate—bone cancer	0.000331	0.00204	CcSEcCtD
Alprazolam—Cardiac disorder—Epirubicin—bone cancer	0.00033	0.00204	CcSEcCtD
Alprazolam—Hepatitis—Doxorubicin—bone cancer	0.000329	0.00203	CcSEcCtD
Alprazolam—Hypoaesthesia—Doxorubicin—bone cancer	0.000327	0.00202	CcSEcCtD
Alprazolam—Midazolam—CYP3A4—bone cancer	0.000327	0.0449	CrCbGaD
Alprazolam—Urinary tract disorder—Doxorubicin—bone cancer	0.000325	0.00201	CcSEcCtD
Alprazolam—Oedema peripheral—Doxorubicin—bone cancer	0.000324	0.002	CcSEcCtD
Alprazolam—Connective tissue disorder—Doxorubicin—bone cancer	0.000323	0.002	CcSEcCtD
Alprazolam—Angiopathy—Epirubicin—bone cancer	0.000323	0.00199	CcSEcCtD
Alprazolam—Urethral disorder—Doxorubicin—bone cancer	0.000323	0.00199	CcSEcCtD
Alprazolam—Mediastinal disorder—Epirubicin—bone cancer	0.000321	0.00198	CcSEcCtD
Alprazolam—Back pain—Methotrexate—bone cancer	0.00032	0.00197	CcSEcCtD
Alprazolam—Chills—Epirubicin—bone cancer	0.000319	0.00197	CcSEcCtD
Alprazolam—Vomiting—Cisplatin—bone cancer	0.000313	0.00193	CcSEcCtD
Alprazolam—Vision blurred—Methotrexate—bone cancer	0.000312	0.00192	CcSEcCtD
Alprazolam—Mental disorder—Epirubicin—bone cancer	0.000312	0.00192	CcSEcCtD
Alprazolam—Erythema multiforme—Doxorubicin—bone cancer	0.000311	0.00192	CcSEcCtD
Alprazolam—Rash—Cisplatin—bone cancer	0.00031	0.00191	CcSEcCtD
Alprazolam—Dermatitis—Cisplatin—bone cancer	0.00031	0.00191	CcSEcCtD
Alprazolam—Malnutrition—Epirubicin—bone cancer	0.00031	0.00191	CcSEcCtD
Alprazolam—Eye disorder—Doxorubicin—bone cancer	0.000308	0.0019	CcSEcCtD
Alprazolam—Ill-defined disorder—Methotrexate—bone cancer	0.000307	0.00189	CcSEcCtD
Alprazolam—Tinnitus—Doxorubicin—bone cancer	0.000307	0.00189	CcSEcCtD
Alprazolam—Cardiac disorder—Doxorubicin—bone cancer	0.000305	0.00188	CcSEcCtD
Alprazolam—Tension—Epirubicin—bone cancer	0.000304	0.00187	CcSEcCtD
Alprazolam—Nervousness—Epirubicin—bone cancer	0.000301	0.00186	CcSEcCtD
Alprazolam—Back pain—Epirubicin—bone cancer	0.000299	0.00185	CcSEcCtD
Alprazolam—Angiopathy—Doxorubicin—bone cancer	0.000299	0.00184	CcSEcCtD
Alprazolam—Malaise—Methotrexate—bone cancer	0.000298	0.00184	CcSEcCtD
Alprazolam—Muscle spasms—Epirubicin—bone cancer	0.000298	0.00184	CcSEcCtD
Alprazolam—Vertigo—Methotrexate—bone cancer	0.000297	0.00183	CcSEcCtD
Alprazolam—Mediastinal disorder—Doxorubicin—bone cancer	0.000297	0.00183	CcSEcCtD
Alprazolam—Chills—Doxorubicin—bone cancer	0.000295	0.00182	CcSEcCtD
Alprazolam—Nausea—Cisplatin—bone cancer	0.000292	0.0018	CcSEcCtD
Alprazolam—Vision blurred—Epirubicin—bone cancer	0.000292	0.0018	CcSEcCtD
Alprazolam—Mental disorder—Doxorubicin—bone cancer	0.000288	0.00178	CcSEcCtD
Alprazolam—Ill-defined disorder—Epirubicin—bone cancer	0.000287	0.00177	CcSEcCtD
Alprazolam—Convulsion—Methotrexate—bone cancer	0.000287	0.00177	CcSEcCtD
Alprazolam—Malnutrition—Doxorubicin—bone cancer	0.000286	0.00177	CcSEcCtD
Alprazolam—Agitation—Epirubicin—bone cancer	0.000285	0.00176	CcSEcCtD
Alprazolam—Arthralgia—Methotrexate—bone cancer	0.000282	0.00174	CcSEcCtD
Alprazolam—Chest pain—Methotrexate—bone cancer	0.000282	0.00174	CcSEcCtD
Alprazolam—Myalgia—Methotrexate—bone cancer	0.000282	0.00174	CcSEcCtD
Alprazolam—Tension—Doxorubicin—bone cancer	0.000281	0.00173	CcSEcCtD
Alprazolam—Diazepam—CYP3A4—bone cancer	0.00028	0.0385	CrCbGaD
Alprazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00028	0.00173	CcSEcCtD
Alprazolam—Malaise—Epirubicin—bone cancer	0.000279	0.00172	CcSEcCtD
Alprazolam—GABRA1—SIDS Susceptibility Pathways—FEV—bone cancer	0.000279	0.027	CbGpPWpGaD
Alprazolam—Discomfort—Methotrexate—bone cancer	0.000278	0.00172	CcSEcCtD
Alprazolam—Nervousness—Doxorubicin—bone cancer	0.000278	0.00172	CcSEcCtD
Alprazolam—Vertigo—Epirubicin—bone cancer	0.000278	0.00172	CcSEcCtD
Alprazolam—Syncope—Epirubicin—bone cancer	0.000278	0.00171	CcSEcCtD
Alprazolam—Back pain—Doxorubicin—bone cancer	0.000277	0.00171	CcSEcCtD
Alprazolam—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000277	0.0268	CbGpPWpGaD
Alprazolam—Muscle spasms—Doxorubicin—bone cancer	0.000275	0.0017	CcSEcCtD
Alprazolam—Palpitations—Epirubicin—bone cancer	0.000274	0.00169	CcSEcCtD
Alprazolam—Confusional state—Methotrexate—bone cancer	0.000272	0.00168	CcSEcCtD
Alprazolam—Loss of consciousness—Epirubicin—bone cancer	0.000272	0.00168	CcSEcCtD
Alprazolam—Vision blurred—Doxorubicin—bone cancer	0.00027	0.00167	CcSEcCtD
Alprazolam—Convulsion—Epirubicin—bone cancer	0.000268	0.00166	CcSEcCtD
Alprazolam—Infection—Methotrexate—bone cancer	0.000268	0.00166	CcSEcCtD
Alprazolam—Ill-defined disorder—Doxorubicin—bone cancer	0.000266	0.00164	CcSEcCtD
Alprazolam—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000265	0.0257	CbGpPWpGaD
Alprazolam—Nervous system disorder—Methotrexate—bone cancer	0.000265	0.00163	CcSEcCtD
Alprazolam—Arthralgia—Epirubicin—bone cancer	0.000264	0.00163	CcSEcCtD
Alprazolam—Chest pain—Epirubicin—bone cancer	0.000264	0.00163	CcSEcCtD
Alprazolam—Myalgia—Epirubicin—bone cancer	0.000264	0.00163	CcSEcCtD
Alprazolam—Agitation—Doxorubicin—bone cancer	0.000263	0.00162	CcSEcCtD
Alprazolam—Anxiety—Epirubicin—bone cancer	0.000263	0.00162	CcSEcCtD
Alprazolam—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.000262	0.0254	CbGpPWpGaD
Alprazolam—Skin disorder—Methotrexate—bone cancer	0.000262	0.00162	CcSEcCtD
Alprazolam—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000262	0.00162	CcSEcCtD
Alprazolam—Hyperhidrosis—Methotrexate—bone cancer	0.000261	0.00161	CcSEcCtD
Alprazolam—Discomfort—Epirubicin—bone cancer	0.00026	0.00161	CcSEcCtD
Alprazolam—Malaise—Doxorubicin—bone cancer	0.000258	0.00159	CcSEcCtD
Alprazolam—Dry mouth—Epirubicin—bone cancer	0.000258	0.00159	CcSEcCtD
Alprazolam—Vertigo—Doxorubicin—bone cancer	0.000257	0.00159	CcSEcCtD
Alprazolam—Anorexia—Methotrexate—bone cancer	0.000257	0.00159	CcSEcCtD
Alprazolam—Syncope—Doxorubicin—bone cancer	0.000257	0.00159	CcSEcCtD
Alprazolam—Confusional state—Epirubicin—bone cancer	0.000255	0.00157	CcSEcCtD
Alprazolam—Palpitations—Doxorubicin—bone cancer	0.000253	0.00156	CcSEcCtD
Alprazolam—Oedema—Epirubicin—bone cancer	0.000253	0.00156	CcSEcCtD
Alprazolam—Hypotension—Methotrexate—bone cancer	0.000252	0.00156	CcSEcCtD
Alprazolam—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000252	0.0244	CbGpPWpGaD
Alprazolam—Loss of consciousness—Doxorubicin—bone cancer	0.000252	0.00155	CcSEcCtD
Alprazolam—Infection—Epirubicin—bone cancer	0.000251	0.00155	CcSEcCtD
Alprazolam—Shock—Epirubicin—bone cancer	0.000249	0.00153	CcSEcCtD
Alprazolam—Convulsion—Doxorubicin—bone cancer	0.000248	0.00153	CcSEcCtD
Alprazolam—Nervous system disorder—Epirubicin—bone cancer	0.000248	0.00153	CcSEcCtD
Alprazolam—Tachycardia—Epirubicin—bone cancer	0.000247	0.00152	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000246	0.00152	CcSEcCtD
Alprazolam—Skin disorder—Epirubicin—bone cancer	0.000245	0.00151	CcSEcCtD
Alprazolam—Hyperhidrosis—Epirubicin—bone cancer	0.000244	0.00151	CcSEcCtD
Alprazolam—Insomnia—Methotrexate—bone cancer	0.000244	0.00151	CcSEcCtD
Alprazolam—Myalgia—Doxorubicin—bone cancer	0.000244	0.0015	CcSEcCtD
Alprazolam—Chest pain—Doxorubicin—bone cancer	0.000244	0.0015	CcSEcCtD
Alprazolam—Arthralgia—Doxorubicin—bone cancer	0.000244	0.0015	CcSEcCtD
Alprazolam—Anxiety—Doxorubicin—bone cancer	0.000243	0.0015	CcSEcCtD
Alprazolam—Paraesthesia—Methotrexate—bone cancer	0.000242	0.0015	CcSEcCtD
Alprazolam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000242	0.00149	CcSEcCtD
Alprazolam—Discomfort—Doxorubicin—bone cancer	0.000241	0.00149	CcSEcCtD
Alprazolam—Anorexia—Epirubicin—bone cancer	0.000241	0.00149	CcSEcCtD
Alprazolam—Dyspnoea—Methotrexate—bone cancer	0.000241	0.00149	CcSEcCtD
Alprazolam—Somnolence—Methotrexate—bone cancer	0.00024	0.00148	CcSEcCtD
Alprazolam—Dry mouth—Doxorubicin—bone cancer	0.000239	0.00147	CcSEcCtD
Alprazolam—Dyspepsia—Methotrexate—bone cancer	0.000238	0.00147	CcSEcCtD
Alprazolam—Hypotension—Epirubicin—bone cancer	0.000236	0.00146	CcSEcCtD
Alprazolam—Confusional state—Doxorubicin—bone cancer	0.000236	0.00145	CcSEcCtD
Alprazolam—Decreased appetite—Methotrexate—bone cancer	0.000235	0.00145	CcSEcCtD
Alprazolam—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.000234	0.0227	CbGpPWpGaD
Alprazolam—Oedema—Doxorubicin—bone cancer	0.000234	0.00144	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Methotrexate—bone cancer	0.000233	0.00144	CcSEcCtD
Alprazolam—Fatigue—Methotrexate—bone cancer	0.000233	0.00144	CcSEcCtD
Alprazolam—Infection—Doxorubicin—bone cancer	0.000232	0.00143	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00023	0.00142	CcSEcCtD
Alprazolam—Shock—Doxorubicin—bone cancer	0.00023	0.00142	CcSEcCtD
Alprazolam—Nervous system disorder—Doxorubicin—bone cancer	0.000229	0.00141	CcSEcCtD
Alprazolam—Insomnia—Epirubicin—bone cancer	0.000229	0.00141	CcSEcCtD
Alprazolam—Tachycardia—Doxorubicin—bone cancer	0.000228	0.00141	CcSEcCtD
Alprazolam—Skin disorder—Doxorubicin—bone cancer	0.000227	0.0014	CcSEcCtD
Alprazolam—Paraesthesia—Epirubicin—bone cancer	0.000227	0.0014	CcSEcCtD
Alprazolam—Hyperhidrosis—Doxorubicin—bone cancer	0.000226	0.00139	CcSEcCtD
Alprazolam—Dyspnoea—Epirubicin—bone cancer	0.000225	0.00139	CcSEcCtD
Alprazolam—Somnolence—Epirubicin—bone cancer	0.000225	0.00139	CcSEcCtD
Alprazolam—Anorexia—Doxorubicin—bone cancer	0.000223	0.00138	CcSEcCtD
Alprazolam—Feeling abnormal—Methotrexate—bone cancer	0.000222	0.00137	CcSEcCtD
Alprazolam—Dyspepsia—Epirubicin—bone cancer	0.000222	0.00137	CcSEcCtD
Alprazolam—Gastrointestinal pain—Methotrexate—bone cancer	0.000221	0.00136	CcSEcCtD
Alprazolam—Decreased appetite—Epirubicin—bone cancer	0.00022	0.00136	CcSEcCtD
Alprazolam—Hypotension—Doxorubicin—bone cancer	0.000218	0.00135	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Epirubicin—bone cancer	0.000218	0.00135	CcSEcCtD
Alprazolam—Fatigue—Epirubicin—bone cancer	0.000218	0.00134	CcSEcCtD
Alprazolam—Constipation—Epirubicin—bone cancer	0.000216	0.00133	CcSEcCtD
Alprazolam—Urticaria—Methotrexate—bone cancer	0.000214	0.00132	CcSEcCtD
Alprazolam—Abdominal pain—Methotrexate—bone cancer	0.000213	0.00132	CcSEcCtD
Alprazolam—Body temperature increased—Methotrexate—bone cancer	0.000213	0.00132	CcSEcCtD
Alprazolam—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000213	0.00131	CcSEcCtD
Alprazolam—Insomnia—Doxorubicin—bone cancer	0.000211	0.0013	CcSEcCtD
Alprazolam—Paraesthesia—Doxorubicin—bone cancer	0.00021	0.0013	CcSEcCtD
Alprazolam—Dyspnoea—Doxorubicin—bone cancer	0.000208	0.00129	CcSEcCtD
Alprazolam—Feeling abnormal—Epirubicin—bone cancer	0.000208	0.00128	CcSEcCtD
Alprazolam—Somnolence—Doxorubicin—bone cancer	0.000208	0.00128	CcSEcCtD
Alprazolam—Gastrointestinal pain—Epirubicin—bone cancer	0.000207	0.00127	CcSEcCtD
Alprazolam—Dyspepsia—Doxorubicin—bone cancer	0.000206	0.00127	CcSEcCtD
Alprazolam—Decreased appetite—Doxorubicin—bone cancer	0.000203	0.00125	CcSEcCtD
Alprazolam—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000202	0.00125	CcSEcCtD
Alprazolam—Fatigue—Doxorubicin—bone cancer	0.000202	0.00124	CcSEcCtD
Alprazolam—Urticaria—Epirubicin—bone cancer	0.000201	0.00124	CcSEcCtD
Alprazolam—GABRB2—Orphan transporters—TUBB4B—bone cancer	0.0002	0.0194	CbGpPWpGaD
Alprazolam—Constipation—Doxorubicin—bone cancer	0.0002	0.00123	CcSEcCtD
Alprazolam—Abdominal pain—Epirubicin—bone cancer	0.0002	0.00123	CcSEcCtD
Alprazolam—Body temperature increased—Epirubicin—bone cancer	0.0002	0.00123	CcSEcCtD
Alprazolam—Hypersensitivity—Methotrexate—bone cancer	0.000199	0.00123	CcSEcCtD
Alprazolam—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000198	0.0191	CbGpPWpGaD
Alprazolam—GABRA5—Orphan transporters—TUBB4B—bone cancer	0.000195	0.0189	CbGpPWpGaD
Alprazolam—Asthenia—Methotrexate—bone cancer	0.000194	0.0012	CcSEcCtD
Alprazolam—Feeling abnormal—Doxorubicin—bone cancer	0.000193	0.00119	CcSEcCtD
Alprazolam—GABRA3—Orphan transporters—TUBB4B—bone cancer	0.000191	0.0185	CbGpPWpGaD
Alprazolam—Gastrointestinal pain—Doxorubicin—bone cancer	0.000191	0.00118	CcSEcCtD
Alprazolam—Pruritus—Methotrexate—bone cancer	0.000191	0.00118	CcSEcCtD
Alprazolam—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.00019	0.0184	CbGpPWpGaD
Alprazolam—GABRA2—Orphan transporters—TUBB4B—bone cancer	0.000188	0.0182	CbGpPWpGaD
Alprazolam—GABRB3—Orphan transporters—TUBB4B—bone cancer	0.000187	0.0181	CbGpPWpGaD
Alprazolam—Hypersensitivity—Epirubicin—bone cancer	0.000186	0.00115	CcSEcCtD
Alprazolam—Urticaria—Doxorubicin—bone cancer	0.000186	0.00115	CcSEcCtD
Alprazolam—Body temperature increased—Doxorubicin—bone cancer	0.000185	0.00114	CcSEcCtD
Alprazolam—Abdominal pain—Doxorubicin—bone cancer	0.000185	0.00114	CcSEcCtD
Alprazolam—Diarrhoea—Methotrexate—bone cancer	0.000185	0.00114	CcSEcCtD
Alprazolam—GABRG2—Orphan transporters—TUBB4B—bone cancer	0.000183	0.0178	CbGpPWpGaD
Alprazolam—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000183	0.0177	CbGpPWpGaD
Alprazolam—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000182	0.0177	CbGpPWpGaD
Alprazolam—Asthenia—Epirubicin—bone cancer	0.000181	0.00112	CcSEcCtD
Alprazolam—Pruritus—Epirubicin—bone cancer	0.000179	0.0011	CcSEcCtD
Alprazolam—Dizziness—Methotrexate—bone cancer	0.000179	0.0011	CcSEcCtD
Alprazolam—GABRB2—Orphan transporters—TUBB2A—bone cancer	0.000173	0.0168	CbGpPWpGaD
Alprazolam—Diarrhoea—Epirubicin—bone cancer	0.000173	0.00107	CcSEcCtD
Alprazolam—Hypersensitivity—Doxorubicin—bone cancer	0.000172	0.00106	CcSEcCtD
Alprazolam—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000172	0.0166	CbGpPWpGaD
Alprazolam—Vomiting—Methotrexate—bone cancer	0.000172	0.00106	CcSEcCtD
Alprazolam—Rash—Methotrexate—bone cancer	0.00017	0.00105	CcSEcCtD
Alprazolam—Dermatitis—Methotrexate—bone cancer	0.00017	0.00105	CcSEcCtD
Alprazolam—Headache—Methotrexate—bone cancer	0.000169	0.00104	CcSEcCtD
Alprazolam—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000169	0.0164	CbGpPWpGaD
Alprazolam—GABRA5—Orphan transporters—TUBB2A—bone cancer	0.000168	0.0163	CbGpPWpGaD
Alprazolam—Asthenia—Doxorubicin—bone cancer	0.000168	0.00104	CcSEcCtD
Alprazolam—Dizziness—Epirubicin—bone cancer	0.000167	0.00103	CcSEcCtD
Alprazolam—Pruritus—Doxorubicin—bone cancer	0.000165	0.00102	CcSEcCtD
Alprazolam—GABRA3—Orphan transporters—TUBB2A—bone cancer	0.000165	0.016	CbGpPWpGaD
Alprazolam—GABRA2—Orphan transporters—TUBB2A—bone cancer	0.000162	0.0157	CbGpPWpGaD
Alprazolam—GABRB3—Orphan transporters—TUBB2A—bone cancer	0.000161	0.0156	CbGpPWpGaD
Alprazolam—Vomiting—Epirubicin—bone cancer	0.000161	0.000991	CcSEcCtD
Alprazolam—Nausea—Methotrexate—bone cancer	0.00016	0.00099	CcSEcCtD
Alprazolam—GABRA1—Orphan transporters—TUBB4B—bone cancer	0.00016	0.0155	CbGpPWpGaD
Alprazolam—Diarrhoea—Doxorubicin—bone cancer	0.00016	0.000987	CcSEcCtD
Alprazolam—Rash—Epirubicin—bone cancer	0.000159	0.000983	CcSEcCtD
Alprazolam—Dermatitis—Epirubicin—bone cancer	0.000159	0.000982	CcSEcCtD
Alprazolam—Headache—Epirubicin—bone cancer	0.000158	0.000977	CcSEcCtD
Alprazolam—GABRG2—Orphan transporters—TUBB2A—bone cancer	0.000158	0.0153	CbGpPWpGaD
Alprazolam—Dizziness—Doxorubicin—bone cancer	0.000155	0.000954	CcSEcCtD
Alprazolam—Nausea—Epirubicin—bone cancer	0.00015	0.000926	CcSEcCtD
Alprazolam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00015	0.0145	CbGpPWpGaD
Alprazolam—Vomiting—Doxorubicin—bone cancer	0.000149	0.000917	CcSEcCtD
Alprazolam—Rash—Doxorubicin—bone cancer	0.000147	0.00091	CcSEcCtD
Alprazolam—Dermatitis—Doxorubicin—bone cancer	0.000147	0.000909	CcSEcCtD
Alprazolam—Headache—Doxorubicin—bone cancer	0.000146	0.000904	CcSEcCtD
Alprazolam—Nausea—Doxorubicin—bone cancer	0.000139	0.000857	CcSEcCtD
Alprazolam—GABRA1—Orphan transporters—TUBB2A—bone cancer	0.000138	0.0134	CbGpPWpGaD
Alprazolam—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000134	0.013	CbGpPWpGaD
Alprazolam—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00013	0.0126	CbGpPWpGaD
Alprazolam—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000129	0.0125	CbGpPWpGaD
Alprazolam—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000119	0.0115	CbGpPWpGaD
Alprazolam—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000109	0.0106	CbGpPWpGaD
Alprazolam—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000108	0.0104	CbGpPWpGaD
Alprazolam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	9.87e-05	0.00956	CbGpPWpGaD
Alprazolam—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	9.18e-05	0.00889	CbGpPWpGaD
Alprazolam—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.83e-05	0.00856	CbGpPWpGaD
Alprazolam—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	8.74e-05	0.00847	CbGpPWpGaD
Alprazolam—GABRB3—BDNF signaling pathway—EIF2S1—bone cancer	8.66e-05	0.00839	CbGpPWpGaD
Alprazolam—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.88e-05	0.00763	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	7.86e-05	0.00762	CbGpPWpGaD
Alprazolam—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.77e-05	0.00753	CbGpPWpGaD
Alprazolam—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.38e-05	0.00618	CbGpPWpGaD
Alprazolam—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.55e-05	0.00538	CbGpPWpGaD
Alprazolam—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	5.48e-05	0.00531	CbGpPWpGaD
Alprazolam—GABRB2—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.89e-05	0.00474	CbGpPWpGaD
Alprazolam—GABRA5—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.75e-05	0.0046	CbGpPWpGaD
Alprazolam—CYP3A7—Biological oxidations—CYP3A4—bone cancer	4.69e-05	0.00454	CbGpPWpGaD
Alprazolam—GABRA3—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.67e-05	0.00452	CbGpPWpGaD
Alprazolam—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	4.63e-05	0.00448	CbGpPWpGaD
Alprazolam—GABRA2—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.59e-05	0.00444	CbGpPWpGaD
Alprazolam—GABRB3—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.56e-05	0.00441	CbGpPWpGaD
Alprazolam—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.5e-05	0.00436	CbGpPWpGaD
Alprazolam—GABRG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.48e-05	0.00433	CbGpPWpGaD
Alprazolam—GABRB2—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.22e-05	0.00409	CbGpPWpGaD
Alprazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	4.13e-05	0.004	CbGpPWpGaD
Alprazolam—GABRA5—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.1e-05	0.00397	CbGpPWpGaD
Alprazolam—GABRA3—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.03e-05	0.0039	CbGpPWpGaD
Alprazolam—CYP3A7—Biological oxidations—GSTP1—bone cancer	4.01e-05	0.00389	CbGpPWpGaD
Alprazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	4.01e-05	0.00388	CbGpPWpGaD
Alprazolam—GABRA2—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.96e-05	0.00384	CbGpPWpGaD
Alprazolam—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	3.96e-05	0.00383	CbGpPWpGaD
Alprazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	3.94e-05	0.00381	CbGpPWpGaD
Alprazolam—GABRB3—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.93e-05	0.00381	CbGpPWpGaD
Alprazolam—GABRA1—Transmembrane transport of small molecules—TUBB4B—bone cancer	3.91e-05	0.00379	CbGpPWpGaD
Alprazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	3.87e-05	0.00375	CbGpPWpGaD
Alprazolam—GABRG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.86e-05	0.00374	CbGpPWpGaD
Alprazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	3.84e-05	0.00372	CbGpPWpGaD
Alprazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	3.78e-05	0.00366	CbGpPWpGaD
Alprazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	3.46e-05	0.00335	CbGpPWpGaD
Alprazolam—CYP3A5—Biological oxidations—CYP3A4—bone cancer	3.39e-05	0.00329	CbGpPWpGaD
Alprazolam—GABRA1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.38e-05	0.00327	CbGpPWpGaD
Alprazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	3.36e-05	0.00325	CbGpPWpGaD
Alprazolam—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	3.34e-05	0.00324	CbGpPWpGaD
Alprazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	3.3e-05	0.0032	CbGpPWpGaD
Alprazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	3.3e-05	0.0032	CbGpPWpGaD
Alprazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	3.24e-05	0.00314	CbGpPWpGaD
Alprazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	3.22e-05	0.00312	CbGpPWpGaD
Alprazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	3.16e-05	0.00306	CbGpPWpGaD
Alprazolam—GABRB2—Transmission across Chemical Synapses—BRAF—bone cancer	3.1e-05	0.00301	CbGpPWpGaD
Alprazolam—GABRA5—Transmission across Chemical Synapses—BRAF—bone cancer	3.01e-05	0.00292	CbGpPWpGaD
Alprazolam—GABRA3—Transmission across Chemical Synapses—BRAF—bone cancer	2.96e-05	0.00287	CbGpPWpGaD
Alprazolam—GABRA2—Transmission across Chemical Synapses—BRAF—bone cancer	2.91e-05	0.00282	CbGpPWpGaD
Alprazolam—CYP3A5—Biological oxidations—GSTP1—bone cancer	2.9e-05	0.00281	CbGpPWpGaD
Alprazolam—GABRB3—Transmission across Chemical Synapses—BRAF—bone cancer	2.89e-05	0.0028	CbGpPWpGaD
Alprazolam—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	2.86e-05	0.00277	CbGpPWpGaD
Alprazolam—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	2.85e-05	0.00276	CbGpPWpGaD
Alprazolam—GABRG2—Transmission across Chemical Synapses—BRAF—bone cancer	2.84e-05	0.00275	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—NDUFA12—bone cancer	2.81e-05	0.00272	CbGpPWpGaD
Alprazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	2.76e-05	0.00268	CbGpPWpGaD
Alprazolam—GABRB3—BDNF signaling pathway—JUN—bone cancer	2.74e-05	0.00265	CbGpPWpGaD
Alprazolam—GABRB2—Transmission across Chemical Synapses—MDM2—bone cancer	2.6e-05	0.00252	CbGpPWpGaD
Alprazolam—GABRA5—Transmission across Chemical Synapses—MDM2—bone cancer	2.53e-05	0.00245	CbGpPWpGaD
Alprazolam—GABRA1—Transmission across Chemical Synapses—BRAF—bone cancer	2.48e-05	0.0024	CbGpPWpGaD
Alprazolam—GABRA3—Transmission across Chemical Synapses—MDM2—bone cancer	2.48e-05	0.0024	CbGpPWpGaD
Alprazolam—GABRA2—Transmission across Chemical Synapses—MDM2—bone cancer	2.44e-05	0.00236	CbGpPWpGaD
Alprazolam—GABRB3—Transmission across Chemical Synapses—MDM2—bone cancer	2.42e-05	0.00235	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—CYP3A4—bone cancer	2.39e-05	0.00232	CbGpPWpGaD
Alprazolam—GABRG2—Transmission across Chemical Synapses—MDM2—bone cancer	2.38e-05	0.0023	CbGpPWpGaD
Alprazolam—GABRB2—Neuronal System—BRAF—bone cancer	2.38e-05	0.0023	CbGpPWpGaD
Alprazolam—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	2.36e-05	0.00228	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—NT5C3A—bone cancer	2.33e-05	0.00226	CbGpPWpGaD
Alprazolam—GABRA5—Neuronal System—BRAF—bone cancer	2.31e-05	0.00224	CbGpPWpGaD
Alprazolam—GABRA3—Neuronal System—BRAF—bone cancer	2.27e-05	0.0022	CbGpPWpGaD
Alprazolam—GABRA2—Neuronal System—BRAF—bone cancer	2.23e-05	0.00216	CbGpPWpGaD
Alprazolam—GABRB3—Neuronal System—BRAF—bone cancer	2.21e-05	0.00215	CbGpPWpGaD
Alprazolam—GABRA1—SIDS Susceptibility Pathways—JUN—bone cancer	2.2e-05	0.00213	CbGpPWpGaD
Alprazolam—GABRG2—Neuronal System—BRAF—bone cancer	2.17e-05	0.00211	CbGpPWpGaD
Alprazolam—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.08e-05	0.00202	CbGpPWpGaD
Alprazolam—GABRA1—Transmission across Chemical Synapses—MDM2—bone cancer	2.08e-05	0.00201	CbGpPWpGaD
Alprazolam—CYP2C9—Biological oxidations—GSTP1—bone cancer	2.04e-05	0.00198	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—NDUFA12—bone cancer	2.03e-05	0.00197	CbGpPWpGaD
Alprazolam—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	2.02e-05	0.00195	CbGpPWpGaD
Alprazolam—GABRB2—Neuronal System—MDM2—bone cancer	1.99e-05	0.00193	CbGpPWpGaD
Alprazolam—GABRA5—Neuronal System—MDM2—bone cancer	1.94e-05	0.00187	CbGpPWpGaD
Alprazolam—GABRA1—Neuronal System—BRAF—bone cancer	1.9e-05	0.00184	CbGpPWpGaD
Alprazolam—GABRA3—Neuronal System—MDM2—bone cancer	1.9e-05	0.00184	CbGpPWpGaD
Alprazolam—GABRA2—Neuronal System—MDM2—bone cancer	1.87e-05	0.00181	CbGpPWpGaD
Alprazolam—GABRB3—Neuronal System—MDM2—bone cancer	1.86e-05	0.0018	CbGpPWpGaD
Alprazolam—GABRG2—Neuronal System—MDM2—bone cancer	1.82e-05	0.00176	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—NT5C3A—bone cancer	1.68e-05	0.00163	CbGpPWpGaD
Alprazolam—GABRA1—Neuronal System—MDM2—bone cancer	1.59e-05	0.00154	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—NDUFA12—bone cancer	1.43e-05	0.00139	CbGpPWpGaD
Alprazolam—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.35e-05	0.00131	CbGpPWpGaD
Alprazolam—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.33e-05	0.00129	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—NT5C3A—bone cancer	1.19e-05	0.00115	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—ENO2—bone cancer	1.02e-05	0.000989	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—DHFR—bone cancer	9.47e-06	0.000917	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—NDUFA12—bone cancer	9.45e-06	0.000915	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GNA11—bone cancer	8.85e-06	0.000857	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—CYP3A4—bone cancer	8.02e-06	0.000777	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—NT5C3A—bone cancer	7.83e-06	0.000759	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—ENO2—bone cancer	7.38e-06	0.000715	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—GSTP1—bone cancer	6.86e-06	0.000665	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—DHFR—bone cancer	6.84e-06	0.000663	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GNA11—bone cancer	6.4e-06	0.00062	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—CYP3A4—bone cancer	5.8e-06	0.000562	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—ENO2—bone cancer	5.2e-06	0.000504	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—GSTP1—bone cancer	4.96e-06	0.00048	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—DHFR—bone cancer	4.82e-06	0.000467	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GNA11—bone cancer	4.51e-06	0.000437	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—CYP3A4—bone cancer	4.09e-06	0.000396	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.07e-06	0.000394	CbGpPWpGaD
Alprazolam—CYP3A7—Metabolism—PTGS2—bone cancer	3.55e-06	0.000344	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—GSTP1—bone cancer	3.5e-06	0.000339	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—ENO2—bone cancer	3.43e-06	0.000332	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—DHFR—bone cancer	3.18e-06	0.000308	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GNA11—bone cancer	2.97e-06	0.000288	CbGpPWpGaD
Alprazolam—CYP3A5—Metabolism—PTGS2—bone cancer	2.57e-06	0.000249	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—GSTP1—bone cancer	2.31e-06	0.000223	CbGpPWpGaD
Alprazolam—CYP2C9—Metabolism—PTGS2—bone cancer	1.81e-06	0.000175	CbGpPWpGaD
Alprazolam—CYP3A4—Metabolism—PTGS2—bone cancer	1.19e-06	0.000116	CbGpPWpGaD
